Ardent Health Stock Price, News & Analysis

Ardent Health (NYSE: ARDT) will issue third quarter 2025 results after market close on Wednesday, November 12, 2025. A conference call to review results and host Q&A is scheduled for Thursday, November 13, 2025 at 9:00 a.m. ET. A live webcast and presentation materials will be available in the Investor Relations section at ir.ardenthealth.com. Listeners should access the site at least 15 minutes early to register and install any required audio software.

Teleconference details: North America toll-free 1-888-596-4144, international 1-646-968-2525, access code 4437657. Replay available through November 27, 2025 at North America toll-free 1-800-770-2030 or international 1-647-362-9199 using access code 4437657.

Ardent Health (NYSE: ARDT) has successfully amended and extended its $777.5 million Term Loan Facility. The amendment includes a 50 basis point reduction in the interest rate, from Term SOFR plus 2.75% to Term SOFR plus 2.25%, and extends the maturity to September 2032.

The refinancing is expected to generate annual interest savings of $3.9 million and provides enhanced financial flexibility for the healthcare provider to pursue strategic growth initiatives and community investments.

Ardent Health (NYSE:ARDT), a healthcare provider focused on mid-sized urban communities across the U.S., has announced its participation in three major healthcare investor conferences in September 2025:

• Wells Fargo Healthcare Conference in Boston (September 4, 8:45 a.m. ET)
• Morgan Stanley Global Healthcare Conference in New York City (September 8, 7:45 a.m. ET)
• Jefferies Healthcare Services Conference in Nashville (September 29, 10:45 a.m. ET)

Management will participate in fireside chats at each event, with live webcasts available on the company's investor relations website. One-on-one meetings with registered investors will also be available.

Ardent Health (NYSE:ARDT) reported strong Q2 2025 financial results with notable growth across key metrics. The company achieved total revenue of $1.65 billion, representing an 11.9% year-over-year increase, and net income of $73 million ($0.52 per diluted share).

Key performance highlights include a 38.9% increase in Adjusted EBITDA to $170 million, 6.6% growth in admissions, and 10.2% growth in net patient service revenue per adjusted admission. The company's lease-adjusted net leverage ratio improved to 2.7x from 3.0x in Q1.

Ardent Health reaffirmed its 2025 guidance with projected total revenue of $6.2-6.45 billion and Adjusted EBITDA of $575-615 million. The company continues to expand its ambulatory care network with plans to open five urgent care centers and two imaging care centers before year-end.

Ardent Health (NYSE:ARDT), a healthcare provider focused on mid-sized urban communities across the U.S., has scheduled its second quarter 2025 earnings release for Tuesday, August 5, 2025, after market close.

The company will host a conference call and webcast on Wednesday, August 6, 2025, at 10 a.m. ET to discuss the results. The webcast and presentation materials will be available on the company's investor relations website. A replay will be accessible through August 20, 2025.

Ardent Health Partners (NYSE: ARDT) announced that its board of directors has approved a corporate name change to Ardent Health, Inc., effective June 3, 2025. The healthcare provider, which operates in growing mid-sized urban communities across the U.S., is aligning its legal name with its commonly used brand identity "Ardent Health". The name change will not affect the company's NYSE trading symbol (ARDT), CUSIP number, or stockholder rights.

Ardent Health (NYSE: ARDT) has appointed Chris Schoeplein as its new chief development officer to spearhead the company's strategic growth initiatives. Schoeplein, who previously served as senior vice president at Kaufman Hall's mergers and acquisitions practice, brings nearly two decades of healthcare strategy and development experience to the role.

In his new position, Schoeplein will be responsible for leading development efforts across Ardent's existing markets and supporting expansion into new regions. His key responsibilities include driving growth in inpatient and outpatient care settings through acquisitions, partnerships, and joint ventures, while also overseeing due diligence, market intelligence, and integration planning.

The appointment comes at what CEO Marty Bonick describes as a "pivotal time" in Ardent's growth journey, as the company aims to scale its consumer-centric platform and extend its joint venture model.

Ardent Health (NYSE: ARDT) reported strong Q1 2025 financial results with total revenue of $1.50 billion, up 4.0% year-over-year. The company achieved net income of $41 million ($0.29 per diluted share) and Adjusted EBITDA of $98 million, growing 2.5% Y/Y. Key operational highlights include a 7.6% increase in admissions and 2.7% growth in adjusted admissions, driven by strong inpatient volumes and heightened flu season. Inpatient surgeries grew 3.4%, while total surgeries declined slightly by 0.7%. The company maintains a solid balance sheet with $495 million in cash and $1.1 billion in total debt. Ardent Health reaffirmed its 2025 guidance, projecting total revenue of $6.2-6.45 billion and Adjusted EBITDA of $575-615 million.

Ardent Health (NYSE: ARDT), a healthcare provider focused on mid-sized urban communities across the U.S., has announced its participation in two major investor conferences in May 2025:

• Bank of America Securities 2025 Health Care Conference in Las Vegas (May 13-14), featuring a presentation on May 14 at 11:40 a.m. ET
• 2025 RBC Capital Markets Global Healthcare Conference in New York City (May 20), including a fireside chat at 8:00 a.m. ET

Live audio webcasts will be available on Ardent Health's investor relations website with 90-day replay access. Management will also conduct one-on-one meetings with registered investors at both conferences.